To read the full story, subscribe or sign in.

OncoMed Has 'Wnt' in its Sails; Bayer Deal Adds $40M Up Front

June 18, 2010

For a firm that has yet to reach Phase II with a lead program, OncoMed Pharmaceuticals Inc. has managed some pretty impressive feats in the past few years. (BioWorld Today)

BioWorld

Bio Korea 2026 kicks off with spotlight on oligonucleotides

BioWorld

Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...

University of Western Australia patents 5-HT2A/B modulators

BioWorld Science

University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...

AA meeting of minds as PTC, Novartis push votoplam in HD

BioWorld

What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...

Innervation can slow, as well as speed, tumor growth, study finds

BioWorld

Innervation by the sympathetic nervous system is typically a boon to tumors. But researchers from Weill Cornell Medicine and colleagues have shown that in some...

Alceptor Therapeutics discovers new α2B-adrenoceptor agonists

BioWorld Science

Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.